NasdaqGS:ADPTLife Sciences
Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer Collaborations and Surging 2024 Share Price
Adaptive Biotechnologies (ADPT) just landed two non exclusive collaborations with Pfizer that lean heavily on its T cell receptor platform, a material win that could reshape both its revenue trajectory and strategic relevance.
See our latest analysis for Adaptive Biotechnologies.
The stock has been on a strong run, with a year to date share price return above 150 percent and a 1 year total shareholder return above 130 percent, helped by growing clonoSEQ adoption, insider selling headlines,...